Document Detail


Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18 952) and prognostic value on treatment outcome.
MedLine Citation:
PMID:  21546857     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Adjuvant therapy with interferon-α (IFN) only benefits a small subgroup of melanoma patients and a predictive marker selecting responders does not exist. IFN induces increased ferritin and decreased C-reactive protein (CRP) levels; however, an association with treatment effect was not studied. Serum was collected from patients participating in the European Organization for Research and Treatment of Cancer 18 952 trial comparing adjuvant treatment with IFN to observation. Serial ferritin and CRP levels were determined using enzyme-linked immusorbent assays, before treatment and up to 24 months. Ferritin levels are influenced by sex and age; therefore ratios of serial ferritin and CRP values with corresponding pretreatment values were calculated. Cox regression model and landmark method at end of induction and 6 months were used to evaluate the association between ferritin, CRP and distant metastasis-free survival (DMFS). Baseline ferritin levels were comparable in the two treatment groups (P=0.92). However, ferritin ratios were significantly higher in IFN-treated patients (N=96) compared with untreated patients (N=21) at end of induction (mean: 2.88 vs. 0.75; P=0.0003) and at 6 months (mean: 3.18 vs. 1.02; P=0.009). In the IFN arm, higher ferritin ratios at end of induction and at 6 months were not associated with improved outcome (respectively, P=0.66 and 0.86). Concerning CRP ratios, no differences between the treatment groups, neither an association with DMFS, were observed. Administration of IFN in melanoma patients induced increase in ferritin levels but not in CRP levels. Ferritin and CRP ratios have no prognostic value regarding DMFS.
Authors:
Marna G Bouwhuis; Sandra Collette; Stefan Suciu; Els R de Groot; Wim H Kruit; Timo L M Ten Hagen; Lucien A Aarden; Alexander M M Eggermont; Antonius J G Swaak
Related Documents :
21277147 - Percutaneous endovenous treatment of congenital extratruncular venous malformations wit...
20428877 - Predicting factors on the occurrence of cystic dilatation of intrahepatic biliary syste...
21108587 - Esomeprazole for the treatment of peptic ulcer bleeding.
16580087 - The diagnostic value of biomarkers (ashtest) for the prediction of alcoholic steato-hep...
17414137 - Long-term treatment with autologous red blood cells loaded with dexamethasone 21-phosph...
2188987 - Transluminal atherectomy for occlusive peripheral vascular disease.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-5-4
Journal Detail:
Title:  Melanoma research     Volume:  -     ISSN:  1473-5636     ISO Abbreviation:  -     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-5-6     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9109623     Medline TA:  Melanoma Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
aDepartment of Surgery, Division Surgical Oncology bDepartment of Medical Oncology, Erasmus University Medical Center - Daniel den Hoed Cancer Center cDepartment of Rheumatology, Ikazia Hospital, Rotterdam dDepartment of Immunopathology, Sanquin Research at CLB, Amsterdam, The Netherlands eDepartment of Statistics, EORTC Headquarters, Brussels, Belgium fInstitut de cancérologie Gustave Roussy, Villejuif, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Circulating microRNA is a biomarker of pediatric Crohn disease.
Next Document:  Placebo effects on analgesia related to testosterone and premotor activation.